Zoetis Inc. (NYSE:ZTS – Get Free Report) Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zoetis Price Performance
Shares of ZTS stock traded down $2.62 on Wednesday, hitting $74.32. 12,798,779 shares of the stock traded hands, compared to its average volume of 4,968,654. The firm has a market cap of $31.16 billion, a price-to-earnings ratio of 12.33, a PEG ratio of 1.25 and a beta of 0.87. Zoetis Inc. has a 52 week low of $74.29 and a 52 week high of $172.23. The firm has a 50 day simple moving average of $115.42 and a two-hundred day simple moving average of $122.28. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.9 earnings per share for the current fiscal year.
Institutional Trading of Zoetis
Wall Street Analysts Forecast Growth
ZTS has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $141.25.
Read Our Latest Report on Zoetis
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
